Anthera Pharmaceuticals (ANTH) : 4 analysts are covering Anthera Pharmaceuticals (ANTH) and their average rating on the stock is 1, which is read as a Strong Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels.
Anthera Pharmaceuticals (ANTH) : 4 Wall Street analysts covering Anthera Pharmaceuticals (ANTH) believe that the average level the stock could reach for the short term is $10.75. The maximum price target given is $14 and the minimum target for short term is around $9, hence the standard deviation is calculated at $2.22.
For the current week, the company shares have a recommendation consensus of Buy. Anthera Pharmaceuticals (NASDAQ:ANTH): The stock opened at $3.03 on Thursday but the bulls could not build on the opening and the stock topped out at $3.07 for the day. The stock traded down to $2.99 during the day, due to lack of any buying support eventually closed down at $3.01 with a loss of -0.33% for the day. The stock had closed at $3.02 on the previous day. The total traded volume was 303,251 shares.
In a related news,The (Chief Medical Officer) of Anthera Pharmaceuticals Inc, Hislop Colin sold 12,500 shares at $5.31 on November 13, 2015. The Insider selling transaction had a total value worth of $66,375. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Anthera Pharmaceuticals Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Companys primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others. The Companys second product candidate Sollpura (liprotamase) is a Phase III investigational pancreatic enzyme replacement therapy (PERT) intended for the treatment of patients with exocrine pancreatic insufficiency (EPI) often seen in patients with cystic fibrosis and other conditions.